Relay Therapeutics announced updated interim clinical data for RLY-2608, an investigational inhibitor of PI3Kα designed for patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer. The data, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback